(129 days)
The indications for the Corin TriFit TS Hip as a total hip arthroplasty, and when used in combination with a Corin hemi arthroplasty head, as a hip hemi-arthroplasty, include:
- Non-inflammatory degenerative joint disease including osteoarthritis and avascular necrosis
- Rheumatoid arthritis
- Correction of functional deformity
- Treatment of non-union, femoral neck and trochanteric fractures of the proximal femur
- Developmental dysplasia of the hip (DDH) or congenital dysplasia of the hip (CDH)
The TriFit TS Hip is intended for cementless use only.
The Corin TriFit TS Hip is a double tapered-wedge blade stem design manufactured from Ti6Al4V Titanium alloy (ASTM F-136-08) with a layer of commercially pure titanium (BS ISO 5832-2: 1999) and calcium phosphate(BONIT®)coating(ASTM F1609-08) applied. The TriFit TS Hip is available in a range of sizes in standard and lateralized offsets with a 127° CCD angle. The device isintended to be used with Corin 12/14 modular taper heads.
The TriFit TS Hip is intended to provide increased patient mobility and reduce pain by replacing the damaged hip joint articulation in patients wherethere is evidence of sufficient sound bone to seat and support the components.
Here's a breakdown of the acceptance criteria and study information for the Corin TriFit TS Hip, based on the provided text:
1. Table of Acceptance Criteria and Reported Device Performance
| Acceptance Criteria | Reported Device Performance |
|---|---|
| Femoral Hip Stem Fatigue (ISO 7206-4: 2010): | All 6 stems passed hip stem fatigue testing for 5 million cycles (mc) at 2.3 kN, meeting the acceptance criteria. |
| Femoral Stem Neck Fatigue (ISO 7206-6: 1992 and ASTM F2068-03): | All 6 stems passed stem neck fatigue for 10 mc at 5.34 kN, meeting the acceptance criteria. |
| Minimum Range of Motion (ISO 21535:2009): | The minimum Range of Motion passed its simulation, meeting the acceptance criteria. |
| CPTi Coating Thickness Testing (Guidance Document for Testing Orthopedic Implants With Modified Metallic Surfaces Apposing Bone Or Bone Cement): | Tested for porosity, pore size, thickness, surface roughness, mechanical strength (static tensile, static shear, shear fatigue), and taper abrasion. (Implicitly met acceptance criteria as no issues were reported). |
| Calcium Phosphate Coating (BONIT®) Characterization (FDA's "510(k) Information needed for Hydroxyapatite Coated Orthopedic Implants"): | Characterized. (Implicitly met acceptance criteria as no issues were reported). |
| Dual Nonporous Coating Testing (ASTM F1854): | Underwent additional testing to determine thickness, porosity, and pore diameter of the combined coating, as well as bending fatigue testing. (Implicitly met acceptance criteria as no issues were reported). |
2. Sample Size Used for the Test Set and Data Provenance
- Sample Size for Physical Testing: For both femoral hip stem fatigue and femoral stem neck fatigue, 6 stems were tested. The text does not specify the sample size for the range of motion analysis or the various coating tests, but it indicates these tests were performed on the device or its components.
- Data Provenance: The text does not explicitly state the country of origin for the non-clinical testing. It is implied these tests were conducted as part of the device development and regulatory submission process, likely under controlled laboratory conditions, making them prospective in nature for the purpose of demonstrating device performance against established standards.
3. Number of Experts Used to Establish the Ground Truth for the Test Set and Qualifications of those Experts
- This device approval is based on non-clinical testing (mechanical, material, and performance evaluations), not clinical data or expert interpretation of medical images. Therefore, the concept of "experts establishing ground truth for a test set" in the context of clinical or diagnostic performance is not directly applicable here. The "ground truth" is defined by the established industry standards and test methods (e.g., ISO, ASTM).
4. Adjudication Method for the Test Set
- Not applicable as this is non-clinical performance testing against pre-defined engineering standards, not a diagnostic or clinical efficacy study requiring expert adjudication of results. The results are quantitative measurements against pass/fail criteria.
5. If a Multi-Reader Multi-Case (MRMC) Comparative Effectiveness Study was Done, What Was the Effect Size of How Much Human Readers Improve with AI vs Without AI Assistance
- Not applicable. This document describes the substantial equivalence of a hip prosthesis (a physical medical device), not an AI-assisted diagnostic or triaging tool.
6. If a Standalone (i.e., algorithm only without human-in-the-loop performance) was Done
- Not applicable. This is not a software or AI-based device.
7. The Type of Ground Truth Used
- The "ground truth" for the non-clinical tests was established by international and national engineering standards and specifications (e.g., ISO 7206-4:2010, ISO 7206-6:1992, ASTM F2068-03, ISO 21535:2009, ASTM F1854) and FDA guidance documents for orthopedic implants and coatings. These standards define the physical properties, mechanical endurance, and other performance characteristics that a hip prosthesis must meet.
8. The Sample Size for the Training Set
- Not applicable. The concept of a "training set" refers to data used to train machine learning models. This device is a physical hip prosthesis, and its evaluation is based on non-clinical engineering tests.
9. How the Ground Truth for the Training Set Was Established
- Not applicable, as there is no "training set" in the context of this device's evaluation.
{0}------------------------------------------------
| 3. 510(K) SUMMARY | |||
|---|---|---|---|
| 1. Applicant/Sponsor: | Corin USA10500 University Center DriveSuite 190Tampa, Florida 33612Establishment Registration No.: 1056629 | OCT 5 2012 | |
| 2. Contact Person: | Lucinda GerberRegulatory Affairs AssociateCorin USA813-977-4469lucinda.gerber@coringroup.com | ||
| 3. Date: | May 25, 2012 | ||
| 4. Proprietary Name: | Corin Trifit TS Hip |
-
- Common Name: Hip Prosthesis
- Classification Name: Hip joint metal/ceramic/polymer semi-constrained cemented or nonporous uncemented prosthesis (21CFR 888.3353)
Hip joint femoral (hemi-hip) metal/polymer cemented or uncemented prosthesis (21CFR 888.3390)
Hip joint femoral (hemi-hip) metallic cemented or uncemented prosthesis (21CFR 888.3360)
7. Legally Marketed Devices to which Substantial Equivalence is claimed:
- Biomet Laterlized Taperloc® MicroplastyTM Femoral Components (K062994)
- DePuy Titanium Tri-Lock Hip Stem (K010367) .
- " DePuy Tri-Lock Bone Preservation Stem (K073570)
- " Corin Metafix Hip Stem with Hemi-Arthroplasty (120362)
- · Corin Trinity Acetabular System (K093472)
8. Device Description:
The Corin TriFit TS Hip is a double tapered-wedge blade stem design manufactured from Ti6Al4V Titanium alloy (ASTM F-136-08) with a layer of commercially pure titanium (BS ISO 5832-2: 1999) and calcium phosphate(BONIT®)coating(ASTM F1609-08) applied. The TriFit TS Hip is available in a range of sizes in standard and
{1}------------------------------------------------
lateralized offsets with a 127° CCD angle. The device isintended to be used with Corin 12/14 modular taper heads.
The TriFit TS Hip is intended to provide increased patient mobility and reduce pain by replacing the damaged hip joint articulation in patients wherethere is evidence of sufficient sound bone to seat and support the components.
9. Intended Use / Indications:
The indications for the Corin TriFit TS Hip as a total hip arthroplasty, and when used in combination with a Corin hemi atthroplasty head, as a hip hemi-arthroplasty, include:
- Non-inflammatory degenerative joint disease including osteoarthritis and avascular 0 necrosis
- Rheumatoid arthritis O
- Correction of functional deformity O
- Treatment of non-union, femoral neck and trochanteric fractures of the proximal 0 femur
- Developmental dysplasia of the hip (DDH) or congenital dysplasia of the hip (CDH) 0
The TriFit TS Hip is intended for cementless use only.
10. Summary of Technologies/Substantial Equivalence:
The TriFit TS Hipis similar to the Biomet Taperloc® MicroplastyTM (K062994) and the DePuy Tri-Lock (K010367, K073570) hip stems in terms of materials, sizes, designs, performance, intended use and indications for use. It is identical to the Corin Metafix Hip Stem (K120362) in terms of intended use and indications and similar in materials. The coating of titanium plasma spray with a layer ofcalcium phosphate(BONIT®) is similar to the coating for the Corin Trinity Acetabular System.(K093472) in terms of materials and performance. Based on these similarities, the TriFit TS Hip is believed to be substantially equivalent to the predicate devices.
11. Non-Clinical Testing:
Non-clinical testing conducted to demonstrate substantial equivalence is consistent with "Guidance for Industry and FDA Staff Non-clinical Information for Femoral Stem Prosthesis" and includes: femoral hip stem fatigue (ISO 7206-4: 2010), femoral stem neck fatigue (ISO 7206-6: 1992 and ASTM F2068-03 Standard Specification for Femoral Prostheses andRange of Motion analysisconsistent with ISO 21535:2009. All 6 stems passed hip stem fatigue testing for 5 million cycles (mc) at 2.3 kN meeting the acceptance criteria. All 6 stems passed stem neck fatigue for 10 mc at 5.34 kN, meeting
{2}------------------------------------------------
K)2.1563 # 3/3
the acceptance criteria. The minimum Range of Motion passed its simulation, meeting the acceptance criteria.
The underlying plasma sprayed CPTi coating thickness was tested for porosity, pore size, thickness, surface roughness, mechanical strength (static tensile, static shear, shear fatigue) and taper abrasion in line with the requirements of 'Guidance Document for Testing Orthopedic Implants With Modified Metallic Surfaces Apposing Bone Or Bone Cement'. The calcium phosphate coating (BONIT®) applied by electrochemical deposition to the CPT coating was characterized per FDA's "510(k) Information needed for Hydroxyapatite Coated Orthopedic Implants." The dual nonporous coating (calcium phosphate coating overlying the CPTi coating) underwent additional testing in order to determine the thickness, porosity and pore diameter of the combined coating in accordance with ASTM F1854, as well as bending fatigue testing.
12. Clinical Testing:
Clinical testing was not necessary to determine substantial equivalence between the additional components of the Corin TriFit TS Hip stem and the predicate devices.
{3}------------------------------------------------
Image /page/3/Picture/1 description: The image shows the logo for the U.S. Department of Health & Human Services. The logo consists of a circular seal with the text "DEPARTMENT OF HEALTH & HUMAN SERVICES - USA" around the perimeter. Inside the circle is an abstract image of an eagle with three stylized lines representing its body and wings.
Food and Drug Administration 10903 New Hampshire Avenue Document Control Room -WO66-G609 Silver Spring. MD 20993-0002
OCT
5 2012
Corin USA % Ms. Lucinda Gerber Regulatory Affairs Associate 10500 University Center Drive, Suite 190 Tampa, Florida 33612
Re: K121563 Trade/Device Name: TriFit TS Hip Regulation Number: 21 CFR 888.3353 Regulation Name: Hip joint metal/ceramic/polymer semi-constrained cemented or nonporous uncemented prosthesis Regulatory Class: Class II Product Code: MEH, LZO, KWL, KWL, KWY Dated: September 07, 2012
Received: September 10, 2012
Dear Ms. Gerber:
We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food. Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration. Please note: CDRH does not evaluate information related to contract liability warranties. We remind you, however, that device labeling must be truthful and not misleading.
If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register.
Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); medical device reporting (reporting of medical
{4}------------------------------------------------
Page 2 – Ms. Lucinda Gerber
comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); medical device reporting (reporting of medical device-related adverse events) (21 CFR 803); good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820); and if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050.
If you desire specific advice for your device on our labeling regulation (21 CFR Part 801), please go to http://www.fda.gov/AboutFDA/CentersOffices/CDRH/CDRHOffices/ucm115809.htm for the Center for Devices and Radiological Health's (CDRH's) Office of Compliance. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21CFR Part 807.97). For questions regarding the reporting of adverse events under the MDR regulation (21 CFR Part 803), please go to
http://www.fda.gov/MedicalDevices/Safety/ReportaProblem/default.htm for the CDRH's Office of Surveillance and Biometrics/Division of Postmarket Surveillance.
You may obtain other general information on your responsibilities under the Act from the Division of Small Manufacturers, International and Consumer Assistance at its toll-free number (800) 638-2041 or (301) 796-7100 or at its Internet address http://www.fda.gov/MedicalDevices/Resourcesfor You/Industry/default.htm.
Sincerely vours.
Sincerely yours,
Erine Keith
C/ Mark N. Melkerson Director Division of Surgical, Orthopedic and Restorative Devices Office of Device Evaluation Center for Devices and Radiological Health
Enclosure
{5}------------------------------------------------
INDICATIONS FOR USE 2.
510(k) Number (if known): K101543
Device Name: TriFit TS Hip
Indications for Use:
The indications for the Corin TriFit TS Hip as a total hip arthroplasty, and when used in combination with a Corin hemi arthroplasty head, as a hip hemi-arthroplasty, include:
- Non-inflammatory degenerative joint disease including osteoarthritis and avascular o necrosis
- Rheumatoid arthritis 0
- Correction of functional deformity O
- Treatment of non-union, femoral neck and trochanteric fractures of the proximal O femur
- Developmental dysplasia of the hip (DDH) or congenital dysplasia of the hip (CDH) o
The TriFit TS Hip is intended for cementless use only.
Prescription Use X (Part 21 CFR 801 Subpart D)
AND/OR
Over-The-Counter Use (21 CFR 801 Subpart C)
(PLEASE DO NOT WRITE BELOW THIS LINE-CONTINUE ON ANOTHER PAGE IF NEEDED)
Concurrence of CDRH, Office of Device Evaluation (ODE)
Ast
(Division Sign-Oft) Division of Surgical, Orthopedic, and Restorative Devices
510(k) Number K121562
Page 1 of _1
§ 888.3353 Hip joint metal/ceramic/polymer semi-constrained cemented or nonporous uncemented prosthesis.
(a)
Identification. A hip joint metal/ceramic/polymer semi-constrained cemented or nonporous uncemented prosthesis is a device intended to be implanted to replace a hip joint. This device limits translation and rotation in one or more planes via the geometry of its articulating surfaces. It has no linkage across-the-joint. The two-part femoral component consists of a femoral stem made of alloys to be fixed in the intramedullary canal of the femur by impaction with or without use of bone cement. The proximal end of the femoral stem is tapered with a surface that ensures positive locking with the spherical ceramic (aluminium oxide, A12 03 ) head of the femoral component. The acetabular component is made of ultra-high molecular weight polyethylene or ultra-high molecular weight polyethylene reinforced with nonporous metal alloys, and used with or without bone cement.(b)
Classification. Class II.